Kristina Jenei joined the department in 2022. Her research focuses on how medicines are prioritised in global health and its impact at country level. She is especially interested in the concept and diffusion of essential cancer medicines.

Prior to joining LSE, Kristina worked as a consultant for the Department of Health Products Policy and Standards at the World Health Organization and a Clinical Reviewer for the Canadian Agency for Drugs and Technology and Health. She completed her Master’s degree in Population and Public Health at the University of British Columbia, where she outlined policy challenges for approving new, expensive cancer medicines. The interest in priority-setting for cancer medicines stems from her experience as a Registered Nurse in Palliative Care. She speaks English and French and is learning Spanish. Kristina’s research has been published in The Lancet, JAMA, British Medical Journal, among others.

Dissertation title:

Essays on the processes and impact of the WHO Model List of Essential Medicines

Dissertation supervisors: 

Huseyin Naci, Olivier Wouters, Elias Mossialos

Publications:

• Jenei K, Raymakers AJN, Bayle A, Berger-Thürmel K, Cherla A, Honda K, Jackson CCGA, Karikios D, Trapani D, Berry S, Gyawali B. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Lancet Oncol. 2023 Jun;24(6):624-635. doi: 10.1016/S1470-2045(23)00175-4. PMID: 37269843.

• Jenei K, Aziz Z, Booth C, Cappello B, Ceppi F, de Vries EGE, Fojo A, Gyawali B, Ilbawi A, Lombe D, Sengar M, Sullivan R, Trapani D, Huttner BD, Moja L. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. Lancet Glob Health. 2022 Dec;10(12):e1860-e1866. doi: 10.1016/S2214-109X(22)00376-X. Epub 2022 Sep 29. PMID: 36183737.

• Meyers DE, Jenei K, Chisamore TM, Gyawali B. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. JAMA Intern Med. 2021 Apr 1;181(4):499-508. doi: 10.1001/jamainternmed.2020.8588. PMID: 33616606; PMCID: PMC7900938.

• Jenei K, Meyers D, Gyawali B. Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020. JAMA Netw Open. 2023 Jan 3;6(1):e2253438. doi: 10.1001/jamanetworkopen.2022.53438. PMID: 36719684; PMCID: PMC9890281.

• Jenei K, Prasad V, Lythgoe MP. High US drug prices have global implications. BMJ. 2022 Mar 22;376:o693. doi: 10.1136/bmj.o693. PMID: 35318198.

• Jenei K, Meyers DE, Prasad V. The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. JAMA Oncol. 2021 Oct 1;7(10):1569-1570. doi: 10.1001/jamaoncol.2021.3686. PMID: 34436541; PMCID: PMC8391769.

• Jenei K, Peacock S, Burgess M, Mitton C. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada. Curr Oncol. 2021 Jul 17;28(4):2708-2719. doi: 10.3390/curroncol28040236. PMID: 34287280; PMCID: PMC8293120.